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BACKGROUND/OBJECTIVES: The aims of the present study are: 1) to quantify sodium consumption of patients with unstable 
or uncontrolled hypertension, 2) to investigate if reduced sodium intake can lower BP in these patients, and 3), to assess 
the acceptability and feasibility of this approach. 
SUBJECTS/METHODS: This study included 25 adults (age: 50+ years) with frequently elevated BP or patients with uncontrolled, 
uncomplicated hypertension despite drug treatment in a general practice setting. BP and salt intake (24h urinary excretion 
and food records) were measured at baseline and after a sodium reduced diet.
RESULTS: Mean (± SD) systolic (SBP) over diastolic (DBP) blood pressure (mmHg) at baseline was 150.7 (± 9.5)/84.149 (± 5.6). 
Mean urinary sodium excretion was 146 mmol/24h. A reduction of 28 mmol sodium excretion decreased SBP/DBP to 135.5 
(± 13.0)/82.5 (± 12.8) (P < 0.001). After one month of no dietary advice, only in 48%, SBP was still ≤140 mmHg. 
CONCLUSION: Assessment of sodium intake using food records, 24h urine collections and probing questions to identify use 
of sodium containing supplements or drugs are essential for tailored advice targeted at sodium intake reduction. The results 
of the present study indicate that reduced sodium intake can lower BP after 4 weeks in unstable or uncontrolled hypertensive 
patients. 
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INTRODUCTION11)
Cardiovascular diseases (CVD) are the leading cause of death 
worldwide [1]. About 54% of strokes and 47% of ischemic heart 
diseases worldwide are attributable to hypertension [2]. 
Furthermore, it has been estimated that 90% of the population 
aged between 55-65 years with normal blood pressure (BP) in 
developed countries will develop hypertension during their 
lifetime [3]. 
It was estimated that almost one third of BP-related deaths 
from coronary heart disease occur in pre-hypertensive indivi-
duals with a systolic BP (SBP) of 120 to 139 mmHg or a diastolic 
BP (DBP) of 80 to 89 mmHg [4]. Therefore, prevention, control 
and treatment of (pre) hypertension remain major public health 
priorities, which can be addressed in general practice as part 
of a broader overall population strategy. Many population- 
based intervention studies showed that even modest decreases 
in BP, could yield substantial reductions in CVD morbidity and 
mortality [1,3,5,6].
The American Heart Association (AHA) recommendations for 
the prevention and treatment of hypertension emphasize non- 
pharmacological therapy, also termed “life-style modification” 
[7]. Large attention is given to a diet rich in vegetables, fish 
and fruits and low in fatty dairy products, as well as limiting 
salt intake and alcohol and maintaining a healthy body weight 
[7]. A large number of studies provide strong evidence of a 
causal link between high salt (sodium chloride) intake, 
hypertension and CVD [1,3,8,9]. The current sodium intake in 
most countries is 150 to 200 mmol per day (9 to 12 g of salt 
per day), while the World Health Organization’s (WHO) 
recommendation is 100 mmol (5 g of salt per day) or less [1].
In the present study we assessed the sodium consumption 
(hidden in food, table salt, effervescent medication and dietary 
supplements) in patients with unstable or uncontrolled BP. The 
main objectives were 1) to quantify sodium consumption 
(hidden in processed foods, table salt, effervescent medication 
and dietary supplements) of patients with unstable or 
uncontrolled hypertension, 2) to assess the effect of a tailored 
dietary advice targeting sodium intake reduction on BP level 
in unstable or uncontrolled hypertensive patients, and 3) to 
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Inclusion criteria Exclusion criteria
An average SBP on 2 of the 3 previous visits of 140 mmHg or more (130 mmHg 
for diabetics) and an average DBP 80 to 100 mmHg
- An active sodium low diet 
- Changing the use of antihypertensive drugs or other medications that would 
affect BP for the past four weeks 
At least 3 of the following criteria: 
1. Using table salt 
2. 2-3 times per week consumption of 
- prepared meals (butchery, warehouse, etc) 
- effervescent tablets 
- smoked fish/meat 
- stock block - broth - soup (self-made or condensed) 
- cookies 
- canned vegetables 
- vegetable juice 
- snacks (chips, cheese, nuts, etc) 
3. Daily consumption of 
- cheese/cold cuts 
- (salted) butter/margarine
- heart failure (ejection fraction < 35) 
- renal insufficiency (creatinine clearance < 60 ml/min)
- secondary hypertension 
- isolated systolic/diastolic hypertension 
- BP difference ≥ 10 mmHg between left and right arm
Blood analysis (fasting glycaemia, creatinine, total cholesterol, high-density 
lipoprotein cholesterol) in the last 6 month
- lactation or pregnancy 
- active malignancy 
- impaired cognitive functioning 
- planning a smoke cessation
BP, Blood pressure; SBP, Systolic blood pressure; DBP, Diastolic blood pressure
Table 1. In- and exclusion criteria for enrollment in the clinical trial
Fig. 1. Schematic overview of the study design. BP; Blood pressure
assess the acceptability of the patients and feasibility of this 
approach in a general practice setting. 
SUBJECTS AND METHODS
Subjects
Patients were recruited during their visit at a general practice 
after screening by a general practitioner who reviewed inclusion 
and exclusion criteria using a standardized screening checklist 
(Table 1). Both male and female patients aged 50 years or older 
with frequent elevated BP with or without antihypertensive 
medication (unstable BP) and patients with uncontrolled, 
uncomplicated hypertension despite medication at pharma-
cologically effective doses (β-blocker, calcium channel blockers, 
diuretics, angiotensin receptor blockers and angiotensin-converting 
inhibitors) were eligible for inclusion. Patients should have an 
average SBP on two of the three previous visits of 140 mmHg 
(130 mmHg in diabetics) or more and an average DBP of 80-100 
mmHg. All subjects had been on a stable antihypertensive 
regimen, including diuretics, for at least four weeks before 
enrollment and no medications were discontinued before evalua-
tion. Exclusion criteria were heart failure, renal insufficiency, 
secondary hypertension or isolated diastolic hypertension, 
lactation/pregnancy, active malignancy, an active low sodium 
diet or changing the use of antihypertensive drugs or other 
medications that would affect BP (e.g. NSAID, oral contraceptive 
hormones, cortisone) four weeks prior to inclusion. 
Study design and protocol
During the first visit, BP was measured (BP1), oral and written 
study information was provided and patients completed a 
general questionnaire. In addition, height and weight were 
measured at inclusion and patients were discouraged to lose 
weight or change exercise habits during the study. BP was 
measured with a hand aneroid sphygmomanometer (Durashock 
DS55) with an appropriate size cuff after 5 minutes of rest with 
the standardized technique according the AHA guidelines [5]. 
Two readings were made at each visit and the average was 
considered for analysis. Body weight and height were measured 
using a flat scale and a wall stadiometer respectively. Body mass 
index was calculated as weight (kg) / height (m)2. Within seven 
days after the first visit, a run-in-period of one week was used 
to collect baseline data. Participants were instructed to follow 
their normal diet and completed a 3-day food record and 
supplied a 24-hour urine collection. In the following weeks, five 
additional visits to the general practice were scheduled (Fig. 
1). During these visits, BP was measured (BP2-BP6). Each study 
visit lasted 15 to 30 minutes. The study visits were free of charge 
and patients were not paid for participation in the study. Based 
on the results of the food records and urinary sodium 
concentration collected during the run-in-period, patients were 
made aware of their dietary sources of sodium and received 
personalized advice to decrease sodium consumption during 
the second visit. This advice consisted of printed education 
materials such as written information about the relation between 
sodium and hypertension, nutritional charts and advice to 
reduce their sodium intake. Each patient intended to change 
his/her diet for at least 28 days taking into consideration the 
provided dietary advice. During the third and fourth visit, 
personal dietary advice was provided based on completed 
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Mean/n SD Median
Age (yrs) 64 (52-77) 7.2 64
Male/female (n) 8/15
Body mass index (kg/m2) 27.4 3.3 27.2
No. of antihypertensive drugs (n) 1 1
AHT: uncontrolled†/unstable‡ (n) 15/8
Diabetes mellitus (n) 2
BP indicates blood pressure
† Uncontrolled, uncomplicated hypertension despite medication at 
pharmacologically effective doses
‡ Frequently elevated BP with or without antihypertensive medications
Table 2. Baseline characteristics of patients who completed the study (n = 23)
3-day food records. After 28 days of dietary intervention, patients 
provided a second 24-hour urine collection and filled in an 
evaluation questionnaire to assess their viewpoint about the 
different procedures and methods used during the trial. One 
month later, during a sixth and final visit, BP was measured 
and after a closing session patients left the study. The field work 
took place between April 2010 and March 2011 in a general 
practice in Bruges, Belgium. The study protocol was approved 
as clinical trial by the ethical committee of the Ghent University 
Hospital (Belgian registration number: B67020108595, study 
number EC/2010/233) and all patients gave written informed 
consent. 
General questionnaire
Patients were asked about their life-style (e.g. smoking status, 
physical activity), nutritional habits (e.g. supplement use, with 
special attention to effervescent tablets) and personal salt 
consumption (e.g. frequency of consumption of table salt, salt 
use during cooking). This questionnaire could be completed at 
home. Patients who returned incomplete questionnaires were 
contacted by phone to obtain any missing information. 
3-day food record
A self-reported 3-day structured record was used to assess 
dietary sodium intake information. Patients were instructed on 
how to complete the food record, also a written example of 
a completed record day was included for future reference. 
Nutrition calculations were performed using the BECEL data 
entry software (version 5.0). The following food composition 
tables were used to perform nutrient calculations: the Belgian 
food composition tables NUBEL (NUBEL, 2004) and the Dutch 
food composition database NEVO (NEVO, 2001). 
24-h urine collections
Patients were provided with two 2L containers and a 1L 
specimen to collect all produced urine during 24 hours. The 
collection started after voiding the first morning urine at 
awakening and continued for 24 hours including one last 
voiding of the bladder the next day. Sodium, chloride and 
potassium in urine were analyzed by ion-selective electrodes 
in the Modular ISE 900-module (Hitachi High-Technologies 
Corporation, Tokyo, Japan). Completeness of the 24-hour urine 
collections was assessed through the ratio creatinine (mg/day)/ 
body mass (kg). Cut off values for a complete collection were
< 25.2 and > 10.8 [10]. Creatinine concentration was analyzed 
by the Jaffé method in the Modular P-800 module (Hitachi 
High-Technologies Corporation, Tokyo, Japan). All samples were 
analyzed in by the same accredited laboratory. 
Participant’s evaluation
Using a set of multiple choice questions, the work-load and 
acceptance of the questionnaires, food records, urine collections, 
dietary advice and visits were scored using relative scores 
ranging from ‘to a low degree’, ‘to some degree’, ‘to a fairly 
high degree’ and ‘to a high degree’. The awareness of the 
patients’ own salt consumption and motivation to continue 
were also considered. The evaluation questionnaire was based 
upon questions asked in the evaluation questionnaire of the 
EFCOVAL study [11]. The answers from this questionnaire, 
allowed us to make an inventory of the problems and barriers 
coinciding our sodium intervention. This information can be 
used to successfully implement this intervention in general 
practice.
Statistical analysis
Statistical tests were performed using SPSS 17.1 (Chicago, IL, 
USA). Baseline BP was calculated as the average of the measure-
ment taken during the screening and run-in period (mean of 
BP1 and BP2). Difference in BP, sodium intake and urinary 
sodium excretion pre and post intervention was computed for 
every patient. Results are reported as means (± SD) and 
medians. A Paired-samples Wilcoxon Signed Rank Tests was 
used to compare sodium intake and urinary sodium excretions. 
Finally, a Friedman test was used to assess differences in SBP 
and DBP and post-hoc tests using Wilcoxon Signed Rank Test 
with Bonferroni correction was used to investigate pairwise 
differences. Unless stated different, a P-value of < 0.05 was used 
as a threshold for significance. 
RESULTS
Subject characteristics
Twenty-five patients were enrolled, 16 females and 9 males. 
Two patients were withdrawn because they needed change in 
antihypertensive medication during the study period. The mean 
age was 64 years (ranging from 52 to 77 years). All baseline 
characteristics are presented in Table 2. Patients used on 
average one antihypertensive drug (ranging from 0 to 3). 
Sodium intake and excretion
Mean sodium intake during normal diet was 161 mmol/day 
(9.3 g of salt) compared to 108.1 mmol/day (6.2 g of salt) during 
the reduced sodium diet (Z = -3.194, P < 0.001) (Table 3). Mean 
urinary sodium excretion during the run-in period was 146.4 
mmol/day (8.4 g of salt) compared to 119 mmol/day (6.8 g of 
salt) after the intervention period (Z = -2.008, P < 0.05).
Blood pressure
The mean BP (mmHg) at baseline was 150.7 (± 9.5)/84.4 (±
5.6) (median 148.3/84.8). After four weeks of intervention, 
systolic and diastolic BP were reduced to 135.5 (± 13.0) mmHg 
(median 135 mmHg) and 82.5 (± 12.8) mmHg (median 80 
mmHg) respectively (χ2(4) = 34.505, P < 0.001 for SBP and χ2(4)
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Mean SD Median P-value
Sodium intake (mmol/d) 
Before intervention (run-in period) 161.1 71.2 159.8 0.002*
After intervention (between visit 4 & 5) 108.1 33.8 113.7
Urinary sodium excretion (mmol/d) 
Before intervention (run-in period) 146.4 57.8 129.0 0.045*
After intervention (between visit 4 & 5) 118.8 42.3 108.0
Systolic blood pressure (mmHg)
SBP baseline ([BP1+BP2]/2) 150.7 9.5 148.3 < 0.001
†
SBP after 7 days diet (BP3) 143.5 11.9 142.3
SBP after 14 days diet (BP4) 139.5 12.6 137.0
SBP after 28 days diet (BP5) 135.5 13.0 135.0
SBP after 30 days of no contact (BP6) 140.7 13.6 140.0
Diastolic blood pressure (mmHg)
DBP baseline ([BP1+BP2]/2) 84.4 5.6 84.8 < 0.001
†
DBP after 7 days diet (BP3) 82.4 5.1 80.5
DBP after 14 days diet (BP4) 81.0 6.0 80.0
DBP after 28 days diet (BP5) 82.5 12.8 80.0
DBP after 30 days of no contact (BP6) 82.8 7.0 81.5
* Wilcoxon signed-rank test
†Friedman test
Table 3. Sodium intake, urinary sodium before and after the dietary intervention
and blood pressure evolution during the trial (n = 23)
= 27.5, P < 0.01 for DBP). Post hoc analysis with Wilcoxon 
signed-rank tests was conducted with a Bonferroni correction 
applied, resulting in a significance level set at P < 0.0125. For 
SBP, there was a significant reduction at all visits compared to 
the baseline values (P < 0.001). For DBP, there were no 
significant differences between baseline BP and the third (BP3) 
and sixth (BP6) measurements (Z = -2.332, P = 0.020 and Z =
-2.876, P = 0.025 respectively).
After one month of no advice at the practice center, 48% 
of the cases had a SBP < 140 mmHg compared to none before 
the start of the intervention (mean SBP 140.7 (± 13.6) mmHg).
Medication and sodium use
Before personalized advice, five patients used daily effervescent 
tablets (paracetamol (527 mg of sodium per tablet) and calcium 
supplements respectively) and three patients used food supple-
ments or over the counter products that could affect BP (St. 
John’s Wort, soda bicarbonate for pyrosis, multivitamin compl-
exes) [5]. During personalized advice, a sodium poor alternative 
was introduced for the calcium supplements (only 10 mg of 
sodium per tablet) and paracetamol was substituted into 
tablets. St. John’s Wort and the vitamins were discontinued and 
the use of soda bicarbonate was minimized. Seven patients 
were using table salt, but all succeeded discontinuing the use. 
Participant’s evaluation
After being informed of the results of the urine collection 
and food records, 15 patients said to be aware of their sodium 
consumption (5 to fairly high degree and 9 to some degree). 
All patients wanted to continue the reduced sodium diet in 
greater or lesser extent. Cited reasons to continue their reduced 
sodium diet included: taking less medication (n = 20) and a 
more healthy life-style (n = 10). Moreover, 19/23 would like to 
have a yearly 24-hour urine collection to check their sodium 
intake and 22/23 would like to redo the trial in the future. 
Seven persons felt constrained to some degree because of 
the diet and 13 persons experienced the diet as a task (3 to 
fairly high degree and 10 to some degree). The largest barriers 
were eating less cold cuts (especially smoked ham, bacon, 
salami), cheese, dressings, smoked fish, using less stock cubes 
and adding less salt to potatoes. Six patients mentioned that 
they experienced problems with the questionnaires and 3 with 
the food records. The 24-hour urine collection gave only in 3 
cases a minor discomfort. All patients declared that their 
24-hour urine collections were complete, which was confirmed 
with the ratio of urinary creatinine (mg/d) to body mass (kg) 
(data not shown). Nobody had problems with the frequency 
of visits.
DISCUSSION
To our knowledge, this is the first study to assess the effects 
of low dietary sodium ingestion in adults aged 50 years or older 
with unstable BP with or without antihypertensive medications 
and patients with unstable or uncontrolled BP despite medi-
cation in a general practice. This trial demonstrated that sodium 
reduction alone can favorably affect BP in hypertensive indivi-
duals. Sodium intake decreased from 161 mmol/24 h (9.3 g of 
salt) to 108 mmol/24 h (6.2 g of salt) and from a 146 mmol/24 
h baseline mean sodium excretion, net decrease was 28 
mmol/24 h after intervention. Corresponding net decreases in 
SBP/DBP were 15.2/1.9 mmHg (P < 0.001). After one month of 
no advice and no contacts, only in 48% of the cases, SBP was 
still ≤ 140 mmHg. 
A remarkable finding in the present trial is that the degree 
of BP reduction was much larger than reductions previously 
observed in unselected hypertensive subjects. For example, in 
a meta-analysis [6], a median reduction in urinary sodium of 
78 mmol/day (4.6 g salt/day) in hypertensive individuals 
lowered SBP and DBP by 5.0 and 2.7 mmHg. The sodium 
reduction in our trial was considerably lower but even yielded 
a larger BP reduction. This suggests that patients with hyper-
tension despite medications or with unstable BP are particularly 
sodium sensitive and it emphasizes the importance of low 
dietary sodium intake in the clinical management of hyper-
tension [12]. 
The best way to study the dose-response relation between 
sodium intake and BP is to look how the BP responds to several 
levels of sodium intake. Only trials lasting more than four weeks 
can show the full effects of long-term reduction in sodium 
intake on BP [6]. In one meta-analysis [6], a median reduction 
in urinary sodium of 78 mmol/day (4.6 g salt/day) in hyperten-
sive individuals lowered SBP and DBP by 5.0 and 2.7 mmHg 
(and 2.0 and 1.0 mmHg in normotensive). There are two 
well-controlled trials that studied three levels of salt intake, each 
for four weeks [13,14]. They all documented statistically signi-
ficant, direct, progressive dose-response relationships. The first 
is a double-blind study in 19 patients with untreated essential 
hypertension. Effects of three different salt levels were tested. 
The BP decreased by 8/5 mmHg when salt intake, as judged 
by 24-hour urinary sodium, changed from 190 to 108 mmol/day 
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(11.1 to 6.3 g of salt/day), and the BP decreased by 8/4 mmHg 
when salt intake changed from 108 to 49 mmol/day (6.3 to 
2.9 g salt/day) [13]. The largest trial is the DASH (Dietary 
Approaches to Stop Hypertension)-Sodium trial which tested 
the effects of three different sodium levels (low (a target of 
2.9 of salt/day), intermediate (a target of 5.8 g of salt/day) and 
high (a target of 8.9 g of salt/day)) on BP in two separate diets: 
the DASH (rich in fruits, vegetables, and low-fat dairy products) 
diet [15] and a control diet (the normal American diet). Both 
the type of diet and sodium reduction were effective in 
lowering BP. Comparing the high- with low-sodium groups, the 
differences in SBP were 6.7 mmHg among those on the control 
diet and 3.0 mmHg among those on the DASH diet. The 
corresponding differences in DBP were 3.5 and 1.6 mmHg 
respectively. These results show that BP can be lowered in either 
a diet that is typical in the US or the DASH diet by reducing 
the sodium intake [14]. 
Our study showed that BP decrease was time dependent. An 
explanation for this time-effect in both DBP and SBP reduction 
could be that during intermediate visits personal advice, tailored 
to the patients’ situation, was provided so sodium intake 
reduction could be further improved with consecutive visits. 
Consequently, with lowering sodium intake in time, BP 
measurement readings also decreased. If we would have been 
able to collect 24h urine collections on all intermediate visits, 
urinary sodium excretion could be analyzed to support this 
hypothesis.
From the evaluation questionnaire, it could be concluded that 
none of the study patients had problems with the (frequency 
of) visits. A possible explanation is that the consultations were 
free of charge. A screening visit and the feedback and advice 
visit lasted minimum 30 minutes, while a regular visit in general 
practice takes about 15 minutes. This time-frame can be a 
potential barrier in future as well as the financial implications 
for the general practitioner. This problem could be overcome 
by referring patients to a skilled dietitian. The costs will increase 
for the patient, unless this is (partly) refunded by the health 
care insurance. This can be done by creating nomenclature 
numbers that attribute more time for the coaching of 
hypertensive patients. A remaining question for further research 
is whether patients are willing to pay extra for BP-coaching and 
if it will be cost-effective for the community. Still, even without 
the assistance of support personnel or programs, physicians 
should routinely encourage life-style modification [4,16,17]. The 
evaluation questionnaire also showed that the reduced sodium 
diet was well tolerated. However some patients experienced the 
diet as a burden, because they had to search for sodium poor 
alternatives for their bread fillings/toppings and had to get used 
to the less salty taste.
Generally, 24-hour urine collections are considered to be the 
most reliable method to evaluate sodium intake because most 
of the sodium a subject consumes is excreted via the urine 
[18]. However, this method is not readily conducted in general 
practice. Although our patients did not mind the urine collections, 
other studies have proposed predictive equations for popula-
tion mean sodium intake based on single spot urine samples 
[19]. Nevertheless, none of the equations presented provided 
unbiased estimates of individual 24-h sodium excretion [19]. 
Screening for the use of supplements (and over the counter 
products) and effervescent tablets is important, since these 
products can affect BP [20]. As patients don’t report sponta-
neously about the use of over the counter products (e.g. soda 
bicarbonate, St. John’s Wort, multivitamins…) or effervescent 
tablets (e.g. calcium supplements, paracetamol), they will only 
be detected by active screening by providing examples. 
A weakness of our study was the low sample size (23 patients). 
Estimation of usual sodium intake is labor intensive. Two 3-day 
food records might be insufficient to represent the usual dietary 
intake among patients, however, the observed decrease in 
sodium intake was also reflected in urinary excretion indicating 
that the food records are capable of detecting relative 
differences in sodium intake. The nutrition calculations were 
performed with databases based on NUBEL-95 and NEVO-96. 
It should be noted that the food composition data used for 
calculating sodium intake might also introduce some bias. 
A control group with the same characteristics as the 
experimental group and not receiving the tailored dietary 
intervention could have been interesting to compare the salt 
intakes and BP reductions. Due to restrictions of available 
budget this was not performed. 
The strengths of the present study include the general practice 
setting (an outpatient setting), its eight-week evaluation and 
the evaluation of several measurements of BP, which is 
important in the management of hypertension. Also, the urine 
collections were an important strength of this study and 
through the multiple follow-up visits, the trial was highly 
controlled. Despite the low sample size, there was a significant 
SBP reduction identified due to the reduced sodium diet (P <
0.001). An extra advantage is the use of food records so that 
sources of salt intake could be determined which allowed 
tailored intervention.
The current challenge in primary care is to reduce sodium 
intake of hypertensive patients and to make sodium restriction 
part of the overall treatment of hypertension. Assessment of 
sodium intake using food records, 24-hour urine collections and 
probing questions to identify use of sodium containing supple-
ments or drugs are essential for tailored advice targeted at 
sodium intake reduction. This trial could serve as a basis for 
further study and development of a guideline for non-pharma-
cological management of hypertension in general practice. 
Further exploration for a good screening form, which is validated, 
and up-to date nutritional charts should be developed for use 
in a general practice. 
This intervention trial shows that in a general practice setting 
significant reductions in both systolic and diastolic blood 
pressure can be achieved in patients with uncontrolled or 
unstable hypertension by lowering sodium intake. Participants’ 
evaluation indicated good acceptance of this approach.
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